← Scroll for more →
C4 Therapeutics, Inc. (CCCC)
Biological Products, (No Diagnostic Substances)
Latest Price
$3.33
TTM P/E
--
Normalized P/E
--
Div Yield
--
Book Value
2.24
P/B Ratio
1.49
Institutional Ownership
93.8% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Morgan Stanley | 8.87M | $41.0M | 7.21% | -205.1K | 2026-06-30 |
| RA Capital Management, L.P. | 8.00M | $37.0M | 6.51% | -- | 2026-06-30 |
| BlackRock, Inc. | 7.90M | $36.0M | 6.43% | +5.85M | 2026-06-30 |
| Squadron Capital Management LLC | 7.60M | $35.0M | 6.18% | +5.35M | 2026-06-30 |
| Lynx1 Capital Management LP | 7.33M | $34.0M | 5.96% | +327.8K | 2026-06-30 |
| Bain Capital Life Sciences Investors, LLC | 7.17M | $33.0M | 5.84% | -- | 2026-06-30 |
| JPMorgan Chase & Co | 4.75M | $20.0M | 3.86% | +4.74M | 2026-06-30 |
| Vanguard Capital Management LLC | 4.42M | $20.0M | 3.59% | +555.9K | 2026-06-30 |
| Citadel Advisors LLC | 4.28M | $20.0M | 3.49% | +1.70M | 2026-06-30 |
| Goldman Sachs Group Inc | 3.53M | $16.0M | 2.87% | +1.14M | 2026-06-30 |